Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Johnson and Johnson
Argus Health
Merck
Novartis
Dow
Farmers Insurance
Express Scripts
McKesson

Generated: February 20, 2018

DrugPatentWatch Database Preview

SANOFI AVENTIS US Company Profile

« Back to Dashboard

Summary for SANOFI AVENTIS US
International Patents:947
US Patents:51
Tradenames:113
Ingredients:93
NDAs:136

Drugs and US Patents for SANOFI AVENTIS US

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No 6,221,633 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Sanofi Aventis Us RIFADIN rifampin CAPSULE;ORAL 062303-001 Approved Prior to Jan 1, 1982 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-001 Sep 12, 2012 RX Yes No 8,802,735 ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us HYGROTON chlorthalidone TABLET;ORAL 012283-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081-001 Apr 20, 2000 RX Yes Yes 7,713,930*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-004 Aug 2, 1996 OTC Yes Yes 9,205,059 ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us SLO-BID theophylline CAPSULE, EXTENDED RELEASE;ORAL 088269-001 Jan 31, 1985 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us SLO-PHYLLIN theophylline TABLET;ORAL 085204-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us GLYBURIDE (MICRONIZED) glyburide TABLET;ORAL 020055-003 Mar 8, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No 8,679,069 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SANOFI AVENTIS US

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us AMBIEN zolpidem tartrate TABLET;ORAL 019908-001 Dec 16, 1992 4,382,938*PED ➤ Try a Free Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA HIVES fexofenadine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021909-003 Jan 24, 2011 6,037,353 ➤ Try a Free Trial
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-001 May 1, 1984 3,507,961 ➤ Try a Free Trial
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-004 Aug 2, 1996 5,508,038 ➤ Try a Free Trial
Sanofi Aventis Us TAXOTERE docetaxel INJECTABLE;INJECTION 020449-004 Aug 2, 2010 5,698,582*PED ➤ Try a Free Trial
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 5,855,912*PED ➤ Try a Free Trial
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-002 Sep 30, 1997 6,342,247*PED ➤ Try a Free Trial
Sanofi Aventis Us ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-010 Jan 24, 2011 5,855,912*PED ➤ Try a Free Trial
Sanofi Aventis Us ARAVA leflunomide TABLET;ORAL 020905-001 Sep 10, 1998 4,351,841 ➤ Try a Free Trial
Sanofi Aventis Us ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-008 Jan 24, 2011 5,855,912*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Transdermal System 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs ➤ Subscribe 5/30/2014
➤ Subscribe Tablets 400 mg ➤ Subscribe 7/1/2013
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 3/23/2011
➤ Subscribe Oral Suspension 30 mg/5 mL ➤ Subscribe 1/25/2010
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 6/30/2009
➤ Subscribe Tablets 300 mg ➤ Subscribe 3/4/2009
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 7/16/2007
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2/9/2007
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2/9/2007
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 12/7/2006
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 6/6/2006
➤ Subscribe Extended-release Tablets 6.25 mg ➤ Subscribe 2/24/2006
➤ Subscribe Extended-release Tablets 12.5 mg ➤ Subscribe 1/19/2006
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 11/10/2004
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 5/25/2004
Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for SANOFI AVENTIS US

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,574,198 Drive mechanisms suitable for use in drug delivery devices ➤ Try a Free Trial
7,205,277 Zinc-free and low-zinc insulin preparations having improved stability ➤ Try a Free Trial
6,100,404 Erythromycin compounds ➤ Try a Free Trial
6,187,916 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor ➤ Try a Free Trial
6,387,946 Methods for treating pathological conditions of abnormal cell proliferation ➤ Try a Free Trial
7,905,867 Pen-type injector ➤ Try a Free Trial
6,004,582 Multi-layered osmotic device ➤ Try a Free Trial
7,622,136 Transparent transdermal nicotine delivery devices ➤ Try a Free Trial
7,205,276 Zinc-free and low-zinc insulin preparations having improved stability ➤ Try a Free Trial
9,028,454 Drive mechanisms suitable for use in drug delivery devices ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for SANOFI AVENTIS US Drugs

Supplementary Protection Certificates for SANOFI AVENTIS US Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90029-5 Sweden ➤ Try a Free Trial PRODUCT NAME: INSULIN DEGLUDEK
90042 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
2002 00001 Denmark ➤ Try a Free Trial DKCTFF , , EXPIRES:
C/GB04/036 United Kingdom ➤ Try a Free Trial PRODUCT NAME: INSULIN DETEMIR, NEB29- TETRADECANOYL- DES(B30) HUMAN INSULIN; NATL REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: CH 56370, 56311, 56372 20031110
90035-0 98910359 Sweden ➤ Try a Free Trial PRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715
/2013 Austria ➤ Try a Free Trial PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
00160 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE DETEMIRUM; NAT. REGISTRATION NO/DATE: EU/1/04/278/001EU/1/04/278/002EU/1/04/278/003EU/1/04/278/005EU/1/04/278/004EU/1/04/278/006EU/1/04/278/007EU/1/04/278/008EU/1/04/278/009 2004010601; FIRST REGISTRATION: 563705637156372EU/1/04/278/001 T/M -/009 2003101110
00446 Netherlands ➤ Try a Free Trial PRODUCT NAME: DRONEDARON, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/09/591/001-004 20091126
6 Finland ➤ Try a Free Trial
13/34 Ireland ➤ Try a Free Trial PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Baxter
Argus Health
Fish and Richardson
McKinsey
Dow
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot